{
    "info": {
        "nct_id": "NCT05364424",
        "official_title": "A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",
        "inclusion_criteria": "* Life expectancy ≥ 12 weeks\n* Histologically confirmed B-cell lymphoma\n* One line of prior systemic therapy including an anti-CD20 monoclonal antibody (i.e. rituximab) and an anthracycline\n* Relapsed or refractory disease after first-line chemoimmunotherapy\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Participant must be a candidate for high-dose chemotherapy followed by ASCT or CAR-T therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Treatment with more than one prior line of therapy for DLBCL\n* Primary mediastinal B-cell lymphoma\n* Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3\n* Peripheral neuropathy assessed to be Grade > 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment\n* Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment\n* Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment\n* Primary or secondary CNS lymphoma at the time of enrollment or history of CNS lymphoma\n* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Known history of progressive multifocal leukoencephalopathy\n* Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia, or as otherwise permitted by inclusion criteria)\n* Prior solid organ transplantation\n* Prior allogeneic stem cell transplant\n* Prior ASCT for lymphoma\n* Prior autologous stem cell transplant for any indication other than lymphoma, within 5 years from the start of study treatment\n* Active autoimmune disease requiring treatment\n* Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 4 weeks prior to first dose of study treatment\n* Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent. Participants who received corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to Cycle 1 Day 1. Participants may have received a brief (≤ 7 days) course of systemic steroids (≤ 100 mg prednisone equivalent per day) prior to initiation of study therapy for control of lymphoma-related symptoms\n* Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis\n* Clinically significant history of cirrhotic liver disease",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Life expectancy ≥ 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed B-cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed B-cell lymphoma",
                    "criterion": "B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": "histology"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be a candidate for high-dose chemotherapy followed by ASCT or CAR-T therapy",
            "criterions": [
                {
                    "exact_snippets": "Participant must be a candidate for high-dose chemotherapy",
                    "criterion": "candidate for high-dose chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "candidate for ... ASCT or CAR-T therapy",
                    "criterion": "candidate for ASCT or CAR-T therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* One line of prior systemic therapy including an anti-CD20 monoclonal antibody (i.e. rituximab) and an anthracycline",
            "criterions": [
                {
                    "exact_snippets": "One line of prior systemic therapy",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including an anti-CD20 monoclonal antibody (i.e. rituximab)",
                    "criterion": "anti-CD20 monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "and an anthracycline",
                    "criterion": "anthracycline therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed or refractory disease after first-line chemoimmunotherapy",
            "criterions": [
                {
                    "exact_snippets": "Relapsed or refractory disease after first-line chemoimmunotherapy",
                    "criterion": "disease status after first-line chemoimmunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Clinically significant history of cirrhotic liver disease",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of cirrhotic liver disease",
                    "criterion": "cirrhotic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary or secondary CNS lymphoma at the time of enrollment or history of CNS lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Primary or secondary CNS lymphoma at the time of enrollment",
                    "criterion": "CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of CNS lymphoma",
                    "criterion": "CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent major surgery (within 4 weeks before the first study treatment) other than for diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Recent major surgery (within 4 weeks before the first study treatment)",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "diagnosis"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 4 weeks prior to first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 4 weeks prior to first dose of study treatment",
                    "criterion": "prior treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first dose of study treatment"
                            }
                        },
                        {
                            "requirement_type": "medication_type",
                            "expected_value": [
                                "cyclophosphamide",
                                "azathioprine",
                                "methotrexate",
                                "thalidomide",
                                "anti-tumor necrosis factor agents"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
                    "criterion": "hemophagocytic lymphohistiocytosis (HLH)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral neuropathy assessed to be Grade > 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment",
            "criterions": [
                {
                    "exact_snippets": "Peripheral neuropathy assessed to be Grade > 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 at enrollment",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity (NCI CTCAE v5.0 grade)",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior autologous stem cell transplant for any indication other than lymphoma, within 5 years from the start of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Prior autologous stem cell transplant for any indication other than lymphoma",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "lymphoma"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 5 years from the start of study treatment",
                    "criterion": "prior autologous stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary mediastinal B-cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Primary mediastinal B-cell lymphoma",
                    "criterion": "primary mediastinal B-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease",
            "criterions": [
                {
                    "exact_snippets": "Current or history of CNS disease",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "epilepsy",
                    "criterion": "epilepsy",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS vasculitis",
                    "criterion": "CNS vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "neurodegenerative disease",
                    "criterion": "neurodegenerative disease",
                    "requirements": [
                        {
                            "requirement_type": "presence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior ASCT for lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Prior ASCT for lymphoma",
                    "criterion": "autologous stem cell transplant (ASCT) for lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring treatment",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring treatment",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with radiotherapy ... within 2 weeks prior to first study treatment",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... chemotherapy ... within 2 weeks prior to first study treatment",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... immunotherapy ... within 2 weeks prior to first study treatment",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... immunosuppressive therapy ... within 2 weeks prior to first study treatment",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment",
                    "criterion": "investigational agent for treating cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell transplant",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with glofitamab",
                    "criterion": "prior treatment with glofitamab",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other bispecific antibodies targeting both CD20 and CD3",
                    "criterion": "prior treatment with bispecific antibodies targeting both CD20 and CD3",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment",
                    "criterion": "treatment with monoclonal antibodies for cancer",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better (with the exception of alopecia and anorexia, or as otherwise permitted by inclusion criteria)",
            "criterions": [
                {
                    "exact_snippets": "Adverse events from prior anti-cancer therapy that have not resolved to Grade 1 or better",
                    "criterion": "adverse events from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia and anorexia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia and anorexia",
                    "criterion": "anorexia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent. Participants who received corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to Cycle 1 Day 1. Participants may have received a brief (≤ 7 days) course of systemic steroids (≤ 100 mg prednisone equivalent per day) prior to initiation of study therapy for control of lymphoma-related symptoms",
            "criterions": [
                {
                    "exact_snippets": "Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who received corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to Cycle 1 Day 1",
                    "criterion": "corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "stability_timepoint",
                            "expected_value": "prior to Cycle 1 Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants may have received a brief (≤ 7 days) course of systemic steroids (≤ 100 mg prednisone equivalent per day) prior to initiation of study therapy",
                    "criterion": "systemic steroid course",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "mg prednisone equivalent per day"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiation of study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of progressive multifocal leukoencephalopathy",
            "criterions": [
                {
                    "exact_snippets": "Known history of progressive multifocal leukoencephalopathy",
                    "criterion": "progressive multifocal leukoencephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with more than one prior line of therapy for DLBCL",
            "criterions": [
                {
                    "exact_snippets": "Treatment with more than one prior line of therapy for DLBCL",
                    "criterion": "prior lines of therapy for DLBCL",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}